Dearborn Dan 4

4 · Kintara Therapeutics, Inc. · Filed Oct 22, 2024

Form 4

Period: 2024-10-18

Chief Financial Officer

Transactions

Award
Options (Right to Buy)
2024-10-18+68,438→ 68,438 total
Exercise: $2.24From: 2024-10-18Exp: 2026-12-20→ Common Stock (68,438 underlying)
Award
Options (Right to Buy)
2024-10-18+232,570→ 232,570 total
Exercise: $3.69Exp: 2032-11-15→ Common Stock (232,570 underlying)
Award
Options (Right to Buy)
2024-10-18+33,991→ 33,991 total
Exercise: $2.24From: 2024-10-18Exp: 2026-01-17→ Common Stock (33,991 underlying)
Award
Options (Right to Buy)
2024-10-18+66,658→ 66,658 total
Exercise: $4.14Exp: 2034-02-28→ Common Stock (66,658 underlying)
Award
Options (Right to Buy)
2024-10-18+15,744→ 15,744 total
Exercise: $3.69Exp: 2033-04-07→ Common Stock (15,744 underlying)

Footnotes (4)

[F1]Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."
[F2]One-third of the stock options become exercisable on the first, second, and third anniversary of November 15, 2023.
[F3]One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023.
[F4]One-third of the stock options become exercisable on the first, second, and third anniversary of February 28, 2024.

Documents

1 file